| Document |
Document Title |
|
WO/2021/240547A2 |
The present invention relates to process for preparation of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxy imino]ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic acid, intermediates, salts and solid forms thereof to pharmaceutical co...
|
|
WO/2021/243093A1 |
The described invention provides compositions and methods for improving or restoring immune system health in a susceptible subject and/or a subject infected with a respiratory virus that impacts the immune system by reducing functional d...
|
|
WO/2021/236771A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2021/233396A1 |
Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomer...
|
|
WO/2021/226276A2 |
Provided are compounds of Formula (II): or a pharmaceutically acceptable salt thereof, wherein R1, n, and Y1 are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula (II), or a ph...
|
|
WO/2021/214502A1 |
The present application provides a method of preparing 4-[3-{3-[(cyclopropylamino)methyl]azetidine-1-carbonyl)-4-fl
uorobenzyl]phthalazin-1(2H)-one, or a pharmaceutically acceptable sail thereof, intermediates in the preparation thereof,...
|
|
WO/2021/209268A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R9 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; X is a bond or a divalent...
|
|
WO/2021/204175A1 |
Provided herein are lipids that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid...
|
|
WO/2021/202781A1 |
Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein L, n, R1, R2, R6, R7, R8, R9, R10, X3, X4 and X5 are defined in the specification. This disclosure also relates to materials and methods for pre...
|
|
WO/2021/195183A1 |
The invention provides compounds that are inhibitors of the protein embryonic ectoderm development (EED), pharmaceutical compositions, their use in modulating the activity of EED, and their use in the treatment of medical disorders, such...
|
|
WO/2021/161887A1 |
[Problem] To provide a novel compound which has high absorption selectivity for the long-wavelength ultraviolet to near ultraviolet region close to a wavelength of 400 nm, exhibits high weathering resistance, and has a merocyanine skelet...
|
|
WO/2021/160680A1 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2021/160920A1 |
Dendrimer-based nanostructures for the diagnosis of allergies to beta-lactam antibiotics and applications. The structure has the formula B-D-L-H-L-D-B, where: H is a hydrophilic polymer (PEG), L is a linker (maleimide), D is a dendrimer ...
|
|
WO/2021/159015A1 |
Provided are compounds of Formula (II) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, and p are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formul...
|
|
WO/2021/150885A1 |
This disclosure provides 8,9-dihydrocannabinoid derivatives, deuterated cannabinoid derivatives, and tritiated cannabinoid derivatives. The disclosure also provides compositions, methods of use, and processes of preparation of the forego...
|
|
WO/2021/147818A1 |
A compound of a structure of formula I having a central nervous system disease treatment effect, which has the activity of a 5-HT2A receptor antagonist or an inverse agonist, has high 5-HT2A receptor selectivity, low cardiotoxicity, and ...
|
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
|
WO/2021/112251A1 |
The present invention addresses the problem of providing a compound that serves as a useful therapeutic medication for systemic lupus erythematosus (SLE) and autoimmune diseases, such as lupus nephritis, in SLE patients by suppressing im...
|
|
WO/2021/106230A1 |
Provided is a phenol compound, or a salt thereof, represented by general formula (I). (In the formula, Ｒ１、Ｒ２、Ｒ５、Ｌ１、Ｌ２、Ｌ３、Ａ、
Ｘ、and ｍ are as defined in the description.)
|
|
WO/2021/097351A1 |
Methods, compounds and compositions for treating and preventing dermatological disorders and ocular irritancy are disclosed. The compounds and compositions comprise a functionalized 1,3-benzene diol, such as 5-(2-(1H-1,2,3-triazol-1-yl)e...
|
|
WO/2021/083209A1 |
Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of...
|
|
WO/2021/078073A1 |
Provided are an N-containing derivative of substituted phenol hydroxy acid ester, and the preparation and use thereof. A compound is represented by formula (I). A salt of the compound of formula (I) has good water solubility, and, in viv...
|
|
WO/2021/081141A1 |
Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthas...
|
|
WO/2021/081375A1 |
Provided herein are inhibitors of receptor tyrosine kinase effector, RAF, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of diseases.
|
|
WO/2021/073629A1 |
Provided in the present application is a compound having the effect of agonizing the SIRT6 acetylation activity or a pharmaceutically acceptable salt thereof, wherein the compound has a structure represented by formula (I). Further provi...
|
|
WO/2021/058024A1 |
Provided are a class of heterospirocyclic compound which act as a lysine-specific demethylase 1 (LSD1) inhibitor, and a use thereof in the preparation of a drug for treating diseases associated with LSD1. The heterospirocyclic compounds ...
|
|
WO/2021/050702A1 |
Provided herein are compounds that inhibit histone lysine demethylase (KDM) and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs ther...
|
|
WO/2021/038490A1 |
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula I as follows: Formula I wherein R1, R2, R3 ...
|
|
WO/2021/033729A1 |
[Problem] The present invention addresses the problem of providing: a compound having an improved balance of agonistic activity to S1P5 receptors in relation to S1P1 receptors; and forms of the compound that are suitable for serving as a...
|
|
WO/2021/022890A1 |
The present invention belongs to the technical field of biomedicine, and specifically relates to a cyclohexanamine D3/D2 receptor partial agonist and a pharmaceutically acceptable salt thereof, and a synthetic method therefor and use the...
|
|
WO/2021/026179A1 |
The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositio...
|
|
WO/2021/018826A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlling...
|
|
WO/2021/020429A1 |
The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof which has the effect of antagonizing the LPA1 receptor.
|
|
WO/2021/018833A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4x, R4y, k and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for c...
|
|
WO/2021/009232A1 |
The present invention relates to compounds of Formula (I), (I) wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controlli...
|
|
WO/2021/009568A1 |
Provided herein are benzenesulfonamide derivatives having Formula (III), pharmaceutical compositions comprising said compounds, and method for using said compounds for disrupting proteins/polypeptides, protein/polypeptide function, and f...
|
|
WO/2021/007663A1 |
This disclosure relates to cannabinoid derivatives of formula (I), pharmaceutical compositions comprising them, and methods of using the cannabinoid derivatives in treating or preventing a diseases associated with a cannabinoid receptor ...
|
|
WO/2020/259366A1 |
Disclosed are a crystal form of a coagulation factor XIa inhibitor and a preparation method therefor, wherein the X-ray powder diffraction pattern of the crystal form comprises diffraction peaks of the 2θ angle at 6.9±0.2°, 15.9±0.2...
|
|
WO/2020/234423A1 |
The presented invention relates to salts of Siponimod with Fumaric acid (1:1) and solid Forms 1 and 2 thereof. The presented invention further relates to salts of Siponimod with Maleic acid (1:1) and solid Forms 1, 2, 3, 4, 5, 6, 7, 8 an...
|
|
WO/2020/219258A1 |
Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, and methods of synthesizing aztreonam derivatives. The aztreonam derivatives can be administered orally to provide orally bioavailable az...
|
|
WO/2020/219876A1 |
The disclosure provides ionizable amine lipids and salts thereof (e.g., pharmaceutically acceptable salts thereof) useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepa...
|
|
WO/2020/174408A9 |
The present application provides novel polymorphic forms of siponimod, their processes, their use in purification of other crystalline polymorphic forms of siponimod, and pharmaceutical compositions containing them. The present applicati...
|
|
WO/2020/208167A1 |
The present invention relates to solid Form 1, Form 2, Form 3 and Form 6 of the compound Siponimod and processes for preparation thereof. The present invention further relates to processes for preparation of solid Form A of the compound ...
|
|
WO/2020/210246A1 |
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical composi...
|
|
WO/2020/206594A1 |
Described are 1, 2, 4-substituted azetidine compounds of formula I, as well as pharmaceutical compositions and dosage forms comprising the compounds, and their use as a medicament. The compounds may find use as antibacterial agents, in p...
|
|
WO/2020/203610A1 |
Provided is a medicinal drug for treating or preventing rheumatoid arthritis. As a medicinal drug for treating or preventing rheumatoid arthritis, the present invention uses, as an active ingredient, a compound that has an effect of bloc...
|
|
WO/2020/201172A1 |
The presented invention relates to a process for preparation of compound of formula (I) or a salt or a solvate thereof (i.e.) siponimod. The invention also relates to intermediates used in the process and solid forms of these intermediates.
|
|
WO/2020/203609A1 |
Provided is a medicinal drug for treating or preventing pruritus. As a medicinal drug for treating or preventing pruritus, the present invention uses, as an active ingredient, a compound that has an effect of blocking the Cav3.2 T-type c...
|
|
WO/2020/193419A1 |
The present invention relates to novel compounds, pharmaceutical compositions comprising such compounds and their use for treating, alleviating or preventing diseases or disorders relating to the activity of potassium channels.
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
